RENNA, SARA
 Distribuzione geografica
Continente #
NA - Nord America 107
EU - Europa 43
AS - Asia 37
SA - Sud America 14
AF - Africa 4
Totale 205
Nazione #
US - Stati Uniti d'America 107
SG - Singapore 26
IT - Italia 18
BR - Brasile 13
IE - Irlanda 10
RU - Federazione Russa 5
DE - Germania 4
VN - Vietnam 4
CN - Cina 3
SN - Senegal 3
CI - Costa d'Avorio 1
EC - Ecuador 1
FR - Francia 1
IL - Israele 1
IQ - Iraq 1
LB - Libano 1
NL - Olanda 1
NO - Norvegia 1
PL - Polonia 1
SE - Svezia 1
TR - Turchia 1
UA - Ucraina 1
Totale 205
Città #
Santa Clara 23
Chandler 19
Singapore 15
Dublin 10
Chicago 9
Ashburn 7
San Giuliano Milanese 5
Wilmington 5
Boardman 4
Civitanova Marche 4
Falls Church 4
Andover 3
Bremen 3
Cambridge 3
Catania 3
Dakar 3
Lawrence 3
Civitavecchia 2
Columbus 2
Council Bluffs 2
Dong Ket 2
Hanoi 2
The Dalles 2
Abidjan 1
Ambato 1
Araçatuba 1
Atlanta 1
Baghdad 1
Barra Mansa 1
Brooklyn 1
Carapicuíba 1
Cinisello Balsamo 1
Den Haag 1
Des Moines 1
Gravataí 1
Itu 1
Jersey City 1
Krasnodar 1
Kyiv 1
Malacacheta 1
Messina 1
Miami 1
Moscow 1
Natal 1
Oslo 1
Pirpirituba 1
Recife 1
Sabará 1
Saint Petersburg 1
São José dos Campos 1
São Paulo 1
Tel Aviv 1
Várzea Paulista 1
Warsaw 1
Totale 166
Nome #
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease 82
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis 66
Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2 64
Totale 212
Categoria #
all - tutte 763
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 763


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 1 0 4 0 1 0 0 5 0 2
2021/202232 5 5 0 1 6 2 4 1 2 0 1 5
2022/202351 3 6 0 9 3 7 0 10 9 0 4 0
2023/202420 1 1 1 1 0 1 7 0 0 0 7 1
2024/202585 0 13 5 6 19 11 4 5 10 4 7 1
2025/20265 5 0 0 0 0 0 0 0 0 0 0 0
Totale 212